A new report from the Association for Accessible Medicines calls for changes to FDA policies, patent law, pharmacy benefit manager practices and federal reimbursement policies that it says are threatening the long-term sustainability of the generic and biosimilar markets.
Human Drugs
Pharming Group’s Joenja Gets Expanded Approval
FDA grants Pharming Group expanded approval for Joenja (leniolisib) tablets for treating activated phosphoinositide 3-kinase delta syndrome in children 4-11 years old.
